thank joining Scott, our you and call for everyone Thanks, to today.
in anticipated XXXX. financial for strengthening grew while welcome to the still the us despite volumes excluding business. a in recovery test the strong XX% have achieve we of a as revenue our activity strong to as Solutions a sequentially. saw half of our results COVID-XX And This The COVID core Molecular of is in we an PCR exceptionally fiscal and second quarter, slowdown to product beginning declined sign to look U.S. normal we revenue, year-over-year the year core more allowed the And XXX% return go, ways our OraSure customers
This milestone Authorizations, with three major Use of Emergency EUAs. quarter, achieved we the also a receipt
in year, to be our important as strategic of to ability and we a InteliSwab, our U.S., InteliSwab the of believe the launch on we of which launch talk the will test incremental a areas driver company. And our and continue of rapid COVID-XX company source about very renewed growth innovation more demonstrates one for focus. test For new coming The of in of pipeline market product our develop, products. focus our the will revenue and
achieving higher priorities, global get quarterly thank testing expanding which both personally our testing launches, a driving As discuss M&A. our to to point focus we world OraSure's I include in results expanding and growth who on us reach the worked reflect and would our our collection into R&D tirelessly dedicated molecular through would exciting sample and innovation strategic strong sample this on and modalities COVID-XX types capitalizing journey. business on services company's like COVID-XX to I and opportunities, our new with our around internal like employees and to now the
of opportunity, First, InteliSwab We for test this for received Use. OTC, Home believe use. rapid and as at differentiated COVID-XX Over-The-Counter competitively the because is primarily remarkably the look testing care simple our EUAs COVID-XX is we point InteliSwab quarter, X to Prescription test we professional
no is there and as lab. to steps, swirl to in outreach adoption with the gentle a absolutely to simplicity anywhere, electricity Unlike simple nostrils confidence including in consumers knows absolute like and a no today. clinicians. use samples our results confusing is rapid no as by ongoing in are tests a used and testing other swab, it's needed swirl see just minutes. crucial tube swab, swab testing and ensures enables batteries, and say your communities, the results to underserved test and this tests, OraSure We your You HCV swab in It HIV COVID mailing where see. no exactly
our customer is new As diagnostics, our three promote in that the conversion early device were medical in customary takes limited this to recall receipt we to of prior time. June. product of purchase orders leads And to EUAs in ability
that Journal in pandemic A a testing. in $XX the conducted over Institutes published June continue the frequent every that did as we are X shipping multiple including focus over So customer and counter as the strategy when fisal acquisition, of of study variants while to equal inquiries currently labeling. recent on at product customer documents to of conducted testing, have be propagation believe governments begin of the We fasting energy indicated based. diseases, and FDA for to orders of will the July. and recently with million, new EUA accept renewed orders locations which Infectious days the global has home. need protection We initial and the that countries in consisting XX in remote vaccination, inquiries we and Health by receive from appropriate supports will country-specific This cutting frequent representing phases such in regular of National
ease crucial a requirements is testing use, most of for where benefit. this real One the type that's of and the InteliSwab of
by and CDC of country's vaccinate. response pandemic the the protect, is program well-characterized test Our to
a continue X-tiered be We critical testing the the will to believe component of response counter to pandemic. COVID-XX that
demand has across global markets. the variants Lambda there been new multiple As such as and in Delta increasing for testing propagate globe,
for programs work, students already and to We've to safety and for believe hygiene around individuals. schools and all. both testing vital we ensuring employees several as return will seen announcements return vaccinated be unvaccinated Additionally, incorporating
suited. and ideally pools is and become of CDC's well have including which our funding for governments, funding from large billion federal available Additionally, for $X.X the the state test underserved communities
the to fund adds billion administration BD That from to testing. of federal surging mitigation funding $XX congregate, COVID-XX from is to, $X.X to rates large BD communities, and billion InteliSwab and communities low testing testing up in to suited. addition our the address and back-to-school vulnerable $XX.X billion now vaccination Administration places In are and address are and in ideally test part, in variants underserved invertible
want our of an responded cover-XX, it Lastly, our tests. and update to as they declined recently as to oral higher us on I FDA review to provide pertains on fluid focus to antibody further The priority. areas submission
as we surveillance interested and to use product a test only COVID-XX applications. laboratories with offer antibody will in However, research several continue this research
example sample our I like trying how one expand collection to of we're Next, to would highlight business.
genomic Saliva generating the standard a and assays collection for of by clearing to often data As space. our you devices sample know portfolio collection we've disrupt in care built type blood relevant co sample with the then
pursuing collection of a noninvasive with to now are Novosanis markets. urine first similar urine look with void new our benefits collection subsidiary as sample We strategy bring the to we
RealTime a virus, detection samples, to sensitivity had for study OraSure's the first clinician the urine publication facilitate cervical oncology, we be human of using void urine HPV, samples quarter, and testing of ability for This significant from neoplasia. of similar demonstrating Colli-Pee, was sample sensitivity and assay to using women, collection the shown collected papilloma High approximately specificity specificity Abbott's the Colli-Pee of samples patients. gynecologic the to of in collected HPV Risk first-void XXX technology proprietary urine In
in we test to studies with have additional year. out HPV come expect process this clinical other manufacturers, We major
where other significant diseases there modality, making future privacy better, has regulatory in cervical transmitted of Colli-Pee's In Health, this their While tests cost-effective full a approval, significant product for of the customers the women collected in decisions top urine Palmetto more million invasive Local for is opportunity. oncology, for of also coverage HPV both regard for still million in for cancer tests. potential transform of a XX greater received commercial This draft contractor significant customers XX to XX catalysts Colli-Pee sexually over alone, cancer testing, own now homes. companies we Typically, for conducting over have our to over validation represents with and Colli-Pee potential The clinical one and to laboratory than have for sample path commercial side, in these types less a microbiome Medicare of believe quarter cervical for we also GBA, We including to Kit risk a and administrative was reimbursement U.S. the screening screening revenue. biopharmaceutical $X saw year studies. per MDX our the market over select using record ongoing cancer service their Determination, are total Coverage prostate adoption MDX microbiome, assessment. test a more the the can XX
Phase based microbiome pharmaceutical working with data of space microbiome companies the the United and Early positive, FDA, around States. samples X studies are of to all the are III these the evaluated as with X to of revenues as well been number increasing XX which lead top advance will in in to has companies top stage increases. as beginning We some a the therapeutics
of kit services our our collection of strategy. is expanding a based eventual microbiome the microbiome our research We we the as half support research. area, toward types, growth pursue analytes service business also an regulatory second believe and important to the in we will benefit therapeutics Building year, our will step business. gut and in customers' further of which investment lead new approval offer sample microbiome Meta-transcriptome Meta-transcriptome strategy multiomic this of to plan on this in This
component unique devices it's recent asked Another Solutions about I important of other long-term market. our highlight position believe us competitive features tech have of our Molecular COVID-XX our launched low the by strategic products. the expanding is and companies, business to Investors important in collection
for Our designed for devices sequencing. collection are remote genetic sampling
shipment analysis, features a the form storage is suitable surveillance of collection as are related In DNA devices to detection storage temperatures. a patented an ambient consumer-friendly variety these capable chemistries use for broad example. designs for and proven, and allowing at easy well in proprietary RNA addition and Because to preserved, of variant the of our stabilizing factors, range under sequencing conditions, sample
for innovate result, do technology, profile. can and not have chemistry, collection, lower are design many devices with COVID our in significant protecting they intellectual property on extending our continually both benefit many there used as match our market the years. physical sample While that out a and cost be expirations We
for collection approvals such year. received their test Helix relationships, are our the increasingly for in with we strategic whole conjunction conjunction this customer regulatory in as exome fluid pursuing Additionally, with our oral device clearance
have key a increasingly long-term We agreements, customer broader services some we and contracts and fulfillment of as customers, to established such range our visibility, providing services. of long-term customization are adding with
base has customer become our diverse. Importantly, in increasingly these markets
testing, single have as of one We representing the in customers than fiscal now of our an this believe with year competitive leaders we revenue global XXXX. home the greater X,XXX position in and we're ability customer diverse genomics, address sample Consequently, additional no strong over X% such extraordinarily ability our in our set expand modalities. with market with to genomics are to our growing solution and as which in markets areas consumer clinical to high-growth mid-teens,
to on and to our global reach presence. strategy our expand Moving
continue of of test approved regulatory We see to in strong test, oral self world. our double-digit self-test HIV internationally, driven annual only HIV by our growth fluid for HIV since the the XXXX adoption OraQuick
to We COVID-XX channels our expand established product our to using registrations rapid Solutions. are several in continues to devices. using we United have test, with where not This outside but increasingly for countries collection spread InteliSwab our Molecular collection XX distribution only global new now continue the also U.S. our HIV OraSure and outside portfolio, States to looking from already COVID-XX the Across applies the for the over we as also XXX increased kits countries. We're the COVID-XX expand reach have diagnostics,
a of opportunities OraSure's to I I'd strength in more M&A. R&D of our to Molecular internal discuss that market focus strategic some build with business infrastructure expertise From diagnostics, on which and simpler, upon business us technologies. a our In additional leverage Solutions, would in new and innovation on effortless allow is. we how important would relating Finally, strategies where in saw testing. growth and priority of higher type we've and in to very us through our standpoint, assessing is active real-time we focused what diagnostics COVID-XX, like of apart sets really just our development companies the provide efforts, to technologies, prioritization expertise. our and this foundation we're testing been our With and spaces recognize a driving like details number existing
to positioned So and the diagnostics, of as the drive ideally about we think is future more Point-Of-Care. testing at self-testing additional OraSure effortless
menu investigating that expand and are We actively a technology competitive differentiation. new global on platforms provide can long-term of our basis tests
believe from capabilities further of positioning growth in stockholder we Overall, looking excited of the there's clients. opportunities internal really at business, input data and with scope quarter our expand which sample our a reach and emerging can about through significant we're our us. broad competitive ensure opportunity areas months XX extremely next at which testing, and to advantage review, stakeholder I'm cash new Solutions in strengthening the $XXX outside will equivalents, innovative currently of we our Molecular and the and M&A. taking We expand the full solutions, further OraSure. of drive We're value outlook into strategic the collection With both our can expertise offer we're external front annual the incorporate expand strategic and ended to cash format, in high-growth services for order million conducting
with investors the broader this within call turn organization. our review of over along look review pleased at occurring look will discuss that, innovation our to to financial the We I'm the complete, output share And results a to Roberto outlook. to with and is the when with
